A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

Vincent, Jean‐Louis; Ramesh, M; Ernest, David; P. LaRosa, Steven; Pachl, Jan; Aikawa, Naoki; A. J. Hoste, Eric; Levy, Howard; Hirman, Joe; Levi, Marcel; Kumar Daga, Mradul; J. Kutsogiannis, Demetrios; Crowther, Mark; R. Bernard, Gordon; Devriendt, Jacques; Vidal Puigserver, Joan; U. Blanzaco, Daniel; T. Esmon, Charles; E. Parrillo, Joseph; M. Guzzi, Louis; Henderson, Seton; Pothirat, Chaicharn; Mehta, Parthiv; Fareed, Jawed; Talwar, Deepak; Tsuruta, Kazuhisa; J. Gorelick, Kenneth; Osawa, Yutaka; Kaul, Inder

doi:10.1097/ccm.0b013e31828e9b03

Public

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

Published in Critical Care Medicine • Aug 27, 2013

Authors:

Jean‐Louis Vincent

M Ramesh

David Ernest

Abstract

OBJECTIVES: To determine the safety and efficacy of recombinant thrombomodulin (ART-123) in patients with suspected sepsis-associated disseminated intravascular coagulation. DESIGN: Phase 2b, international, multicenter, double-blind, randomized, placebo-controlled, parallel group, screening trial. S...

Subject

Medicine

Disseminated intravascular coagulation

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!